Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects
- 1 April 2015
- journal article
- review article
- Published by Elsevier BV in Transfusion and Apheresis Science
- Vol. 52 (2), 240-244
- https://doi.org/10.1016/j.transci.2015.02.013
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV LightTransfusion Medicine and Hemotherapy, 2011
- Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTMTransfusion Medicine and Hemotherapy, 2011
- Main Properties of the THERAFLEX MB-Plasma System for Pathogen ReductionTransfusion Medicine and Hemotherapy, 2011
- The Use of Solvent/Detergent Treatment in Pathogen Reduction of PlasmaTransfusion Medicine and Hemotherapy, 2011
- Pathogen inactivation - regulators aspectsISBT Science Series, 2010
- An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatmentTransfusion, 2010
- INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysisVox Sanguinis, 2009
- Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centersTransfusion, 2008
- A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpuraTransfusion, 2006
- Fundamentals of the psoralen-based Helinx[trade ] technology for inactivation of infectious pathogens and leukocytes in platelets and plasmaSeminars in Hematology, 2001